There is one clinical trial.
The CONTAIN (CiclesOnide cliNical TriAl covId-19 treatmeNt) is a randomized control study of ciclesonide vs placebo for mild covid-19 disease. The need for potential therapy for COVID-19 patients is urgent. Ciclesonide has shown encouraging in vitro results, is easy to be used and is readily available. It has a low rate of side effects and few interactions with other drugs. It is unusual to use an inhaled steroid drug for COVID-19 but there has been new data suggesting steroids may have an antiviral effect in addition to an anti-inflammatory effect. Investigators propose to use inhaled and nasal ciclesonide to stop viral replication in the nose and airways. Investigators hope this will accelerate recovery from COVID-19 illness in individuals who are not admitted to hospital at time of diagnosis of COVID-19.
Description: Proportion of participants with no symptoms of cough, fever or dyspnea at day 7Measure: Proportion of participants with no symptoms of cough, fever or dyspnea Time: day 7
Description: "Dyspnea improvement" is defined as a 15%, or greater, decline in dyspnea intensity using the Promis Dyspnea characteristics scale administered at day 7 in patients who declare dyspnea at day 1. In patients who declare chest tightness/chest congestion/dry or wet cough at study entry we will define a change as a 2-point improvement using a visual analog scale from 0 to 10.Measure: Improvement in dyspnea Time: day7
Description: Hospitalization for SARS-CoV-2 related illness at day 14Measure: Hospitalization for SARS-CoV-2 Time: day 14
Description: Incidence of new oxygen use during the trial (defined as oxygen use not present at randomization) at day 14Measure: Oxygen Use Time: day 14
Description: Duration of new oxygen use during the trial (defined as oxygen use not present at randomization) at day 14Measure: Oxygen Use Time: day 14
Description: All cause mortalityMeasure: Mortality Time: day 14 and 29
Description: Ordinal Scale for evaluating subject Clinical Status from o to 10 ( 0 uninfected and 10 death)Measure: Clinical status Time: day 7 and 14
Description: Patient-Reported Outcomes Measurement Information System (PROMIS)Anxiety 7a scale from 1 to 5 (1never had symptoms and 5 always had symptoms)Measure: Anxiety Time: day 7, 10 and 14
Description: Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep disturbance 4a scale from 1 to 5 (1being very good and 5 being very poor)Measure: Sleep Disturbance Time: day 7, 10 and 14
Description: Visual Analog scale from 0-10 indicating improvement in respiratory symptoms such as chest tightness/chest congestion/dry or wet cough at day 7,10 and14 ( 0 being completely resolved and 10 being the worst they've been)Measure: Visual Analog scale Time: day 7, 10 and 14
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports